Orexo Initiates Phase II Inflammatory Airway Diseases Trial
Posted on: Tuesday, 2 September 2008, 09:00 CDT
Orexo, a Swedish pharmaceutical company, has initiated a Phase II program for the product OX914, a new candidate for the treatment of inflammatory airway diseases including asthma, chronic obstructive pulmonary disease and rhinitis.
The patients will be treated with OX914 in a disease model for inflammatory airway disease. Approximately 36 patients with seasonal allergic rhinitis will be given placebo or OX914 in doses of 15 or 50mg for two weeks in a double-blind three-way cross-over study. Effects on nasal symptoms, inflammatory response, as well as safety and tolerability will be documented.
OX914 is a so-called PDE4 inhibitor with an improved safety profile in development for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and rhinitis.
Torbjorn Bjerke, president and CEO of Orexo, said: "This is Orexo's first NCE in Phase II. OX914 has the potential to be an important new product for the treatment of asthma, COPD and rhinitis with the improved safety profile in particular the lower frequency of nausea and vomiting compared to other PDE4 inhibitors in development. We look forward to results in the first half of 2009."
Source: Datamonitor
Related Articles
- Aerovance Completes Patient Enrollment in Phase 2b Clinical Trial of Aerovant(TM) for Treatment of Uncontrolled Asthma
- ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients
- Teleflex Medical Introduces the Neb-U-Mask for the Treatment of Acute Asthma Exacerbations
- Mometasone Furoate Dry Powder Inhaler: a Once-Daily Inhaled Corticosteroid for the Treatment of Persistent Asthma
- MediciNova Announces the Initiation of the Phase III Clinical Program for MN-001, a Novel Oral Treatment for Bronchial Asthma
- Allergic rhinitis treatment key to asthma control
- Celera Genomics Presents Data Describing the Efficacy of Its Tryptase Inhibitor for the Treatment of Allergic Asthma
- Proton-Pump Inhibitor Therapy for Gastroesophageal Reflux Disease: Does It Treat the Asthma?
- Rigel and Pfizer Sign Collaborative Research and License Agreement for the Treatment of Allergic Asthma and Other Respiratory Diseases
- Zafirlukast Treatment for Acute Asthma*: Evaluation in a Randomized, Double-Blind, Multicenter Trial
 |
 |
User Comments (0)
RSS Feeds